MXPA03011793A - Interferon formulations. - Google Patents

Interferon formulations.

Info

Publication number
MXPA03011793A
MXPA03011793A MXPA03011793A MXPA03011793A MXPA03011793A MX PA03011793 A MXPA03011793 A MX PA03011793A MX PA03011793 A MXPA03011793 A MX PA03011793A MX PA03011793 A MXPA03011793 A MX PA03011793A MX PA03011793 A MXPA03011793 A MX PA03011793A
Authority
MX
Mexico
Prior art keywords
interferon
compositions
interferon formulations
relates
formulations
Prior art date
Application number
MXPA03011793A
Other languages
Spanish (es)
Inventor
Drustrup Jorn
Original Assignee
Maxygen Holdings Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Maxygen Holdings Ltd filed Critical Maxygen Holdings Ltd
Publication of MXPA03011793A publication Critical patent/MXPA03011793A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/565—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

The invention relates to interferon compositions, such as pharmaceutical interferon compositions and methods of their preparation. In particular it relates to stabilized compositions comprising an interferon polypeptide and a sulfoalkyl ether cyclodextrin derivative.
MXPA03011793A 2001-06-29 2002-06-28 Interferon formulations. MXPA03011793A (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DKPA200101040 2001-06-29
DKPA200101277 2001-08-30
DKPA200200257 2002-02-19
PCT/DK2002/000444 WO2003002152A2 (en) 2001-06-29 2002-06-28 Stabilized formulations of interferons with sulfoalkyl ether cyclodextrins

Publications (1)

Publication Number Publication Date
MXPA03011793A true MXPA03011793A (en) 2004-04-02

Family

ID=27222516

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA03011793A MXPA03011793A (en) 2001-06-29 2002-06-28 Interferon formulations.

Country Status (7)

Country Link
EP (1) EP1414498A2 (en)
JP (1) JP2004522803A (en)
CN (1) CN1522159A (en)
CA (1) CA2452364A1 (en)
MX (1) MXPA03011793A (en)
RU (1) RU2004102500A (en)
WO (1) WO2003002152A2 (en)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7959910B2 (en) 2000-07-31 2011-06-14 Biolex Therapeutics, Inc. C-terminally truncated interferon alpha variants
AU2003254641A1 (en) * 2002-08-28 2004-03-19 Maxygen Aps Interferon beta-like molecules for treatment of cancer
US20040126360A1 (en) * 2002-10-09 2004-07-01 Manning Mark C. Oral formulations for proteins and polypeptides
CN102319437B (en) 2002-12-26 2017-10-13 山景医药公司 Polymer conjugates of interferon-beta with enhanced biological utility
CA2547822A1 (en) * 2003-12-11 2005-06-30 Ares Trading S.A. Stabilized interferon liquid formulations
CN1993138B (en) * 2004-06-01 2010-12-15 阿雷斯贸易股份有限公司 Method of stabilizing proteins
CN1984674A (en) * 2004-06-07 2007-06-20 纳斯泰克制药公司 Intranasal formulations of interferon beta free of stabilizers that are proteins or polypeptides
US20060024272A1 (en) * 2004-07-29 2006-02-02 Large Scale Biology Corporation C-terminally truncated interferon
DK1917276T3 (en) * 2005-08-26 2018-05-07 Ares Trading Sa Process for Preparation of Glycosylated Interferon Beta
US20070243163A1 (en) * 2006-02-17 2007-10-18 Chih-Ping Liu Respiratory tract delivery of interferon-tau
US20100260704A1 (en) * 2006-03-08 2010-10-14 Biomethodes Human interferon-gamma (infgamma) variants
JP2008069073A (en) * 2006-09-12 2008-03-27 Yokohama Tlo Co Ltd Lactoferrin conjugate and its manufacturing method
US8617531B2 (en) 2006-12-14 2013-12-31 Bolder Biotechnology, Inc. Methods of making proteins and peptides containing a single free cysteine
EP3766493B1 (en) * 2007-04-27 2023-08-23 CyDex Pharmaceuticals, Inc. Method for improving the stability of clopidogrel using sulfoalkyl ether cyclodextrin
US7625555B2 (en) 2007-06-18 2009-12-01 Novagen Holding Corporation Recombinant human interferon-like proteins
US9138403B2 (en) * 2007-12-20 2015-09-22 Merck Serono Sa PEG-interferon-beta formulations
US10463677B2 (en) 2008-11-07 2019-11-05 Cydex Pharmaceuticals, Inc. Composition containing sulfoalkyl ether cyclodextrin and latanoprost
WO2010057107A1 (en) * 2008-11-17 2010-05-20 Genentech, Inc. Method and formulation for reducing aggregation of a macromolecule under physiological conditions
KR101991367B1 (en) 2009-05-13 2019-06-21 사이덱스 파마슈티칼스, 인크. Pharmaceutical compositions comprising prasugrel and cyclodextrin derivatives and methods of making and using the same
RU2482871C2 (en) * 2010-06-07 2013-05-27 Общество с ограниченной ответственностью "Центр Инновационных Технологий "БиоФарм" (ООО "ЦИТ "БиоФарм") Composition for treating viral diseases in animals
TWI532487B (en) 2011-10-21 2016-05-11 艾伯維有限公司 Method for treating hepatitis C virus (HCV)
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
WO2013059638A1 (en) 2011-10-21 2013-04-25 Abbvie Inc. Combination treatment (eg. with abt-072 or abt -333) of daas for use in treating hcv
US10012064B2 (en) 2015-04-09 2018-07-03 Highlands Natural Resources, Plc Gas diverter for well and reservoir stimulation
US10344204B2 (en) 2015-04-09 2019-07-09 Diversion Technologies, LLC Gas diverter for well and reservoir stimulation
BR112018010945A2 (en) 2015-12-30 2018-12-04 Genentech Inc formulations with reduced polysorbate degradation
US10982520B2 (en) 2016-04-27 2021-04-20 Highland Natural Resources, PLC Gas diverter for well and reservoir stimulation
JP7129703B2 (en) 2016-04-28 2022-09-02 エモリー ユニバーシティー Alkyne-Containing Nucleotide and Nucleoside Therapeutic Compositions and Uses Associated Therewith
WO2017194783A1 (en) * 2016-05-13 2017-11-16 Orionis Biosciences Nv Targeted mutant interferon-beta and uses thereof
CN111358938B (en) * 2020-03-30 2023-08-11 温州肯恩大学(Wenzhou-KeanUniversity) Combination medicine of human interferon-ε and interferon-γ and its application
CN113797317B (en) * 2021-10-26 2024-01-09 科兴生物制药股份有限公司 Composition, and preparation method and application thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5997856A (en) * 1988-10-05 1999-12-07 Chiron Corporation Method and compositions for solubilization and stabilization of polypeptides, especially proteins
US5376645A (en) * 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
US6046177A (en) * 1997-05-05 2000-04-04 Cydex, Inc. Sulfoalkyl ether cyclodextrin based controlled release solid pharmaceutical formulations
PT986403E (en) * 1997-06-13 2004-04-30 Cydex Inc COMPOSITION WITH A LONG-TERM STORAGE LIFE COMPREHENING CYCLODEXTRIN AND DRUGS OR PRODUKES THAT DECOMPOSE IN INSOLULE COMPOUNDS IN WATER

Also Published As

Publication number Publication date
EP1414498A2 (en) 2004-05-06
WO2003002152A3 (en) 2003-05-01
RU2004102500A (en) 2005-04-10
CN1522159A (en) 2004-08-18
WO2003002152A2 (en) 2003-01-09
JP2004522803A (en) 2004-07-29
CA2452364A1 (en) 2003-01-09

Similar Documents

Publication Publication Date Title
MXPA03011793A (en) Interferon formulations.
WO2001058412A3 (en) Extracts from residues left in the production of wine
AU2002305099A1 (en) Fatty alcohol drug conjugates
TWI256891B (en) 17alpha-alkyl-17beta-oxy-estratrienes and intermediate products for their production, use of the 17alpha-alkyl-17beta-oxy-estratrienes for the production of pharmaceutical agents as well as pharmaceutical preparations
WO2004043363A8 (en) Protein-stabilized liposomal formulations of pharmaceutical agents
HUS1800013I1 (en) Oral formulations of cladribine
MY142354A (en) Acidic insulin preparations having improved stability
CA2425005A1 (en) Process for preparing powder formulations
IL159110A0 (en) Small molecule antagonists of bcl2 family proteins
WO2004103390A3 (en) Stable analogs of peptide and polypeptide therapeutics
MXPA04005517A (en) Pharmaceutical compositions in the form of gel or solution based on dihydrotestosterone, preparation method and uses thereof.
WO2001066565A3 (en) In vivo production of cyclic peptides
TWI317736B (en) Methods for the production of redox proteins and heteromultimeric-protein-complexes, and related compositions related applications
WO2001005355A3 (en) Formulations for il-11
MXPA03007857A (en) Compounds and compositions for delivering active agents.
IL160171A0 (en) Depsipeptide derivatives, processes for the preparation thereof and pharmaceutical compositions containing the same
MXPA05010330A (en) Cladribine formulations for improved oral and transmucosal delivery.
DE50213839D1 (en) THIN-LIQUID, SPRAYING W / O EMULSIONS
PL1677818T3 (en) Stable aqueous g-csf-containing compositions
WO2004073686A3 (en) Menthol solutions of drugs
MY138219A (en) Biologically active peptides
AU2002308649A1 (en) Compositions and methods for enhancing drug delivery
WO1999012945A3 (en) Hydrophobic glycosylamine derivatives, compositions, and methods for use
WO2001037780A8 (en) Urotensin-ii analogs
AU2003259750A1 (en) Methods and compositions for targeting secretory lysosomes